Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality and the greatest threat to the health and life of the population. In the past 50 years, many countries have reported that the incidence and mortality of lung cancer have increased significantly. The incidence and mortality of lung cancer in men are the first of all malignant tumors, the incidence of women is the second, and the mortality is the second.

Traditional treatment options for lung cancer include surgery, radiotherapy and chemotherapy. However, surgery cannot remove metastatic lesions and residual tumor cells, and the side effects of radiotherapy and chemotherapy significantly reduce the quality of life of patients. In response to these conditions, patients can choose ACTL treatment.

【Case Introduction】

Today I am sharing a case of ACTL technology in the treatment of lung cancer brain metastases. Relevant information was provided by the Fifth People's Hospital of Dongguan City, and Shenzhen Yishi Kangning provided technical support for ACTL.

In this case, the patient used ACTL technology alone and after four treatments, the serum tumor marker level was reduced, the brain metastasis lesions were significantly reduced, the condition was effectively controlled, and the mental and physical strength were significantly improved.

【Patient Information】

The patient Zhang, male, 74 years old, was admitted to the hospital for more than half a year after surgery for upper right lung cancer, and dizziness worsened by brain metastasis syndrome after radiotherapy and chemotherapy.

The patient had undergone surgery to remove the tumor in 2014, and received systematic radiotherapy and chemotherapy. In March 2015, he was found to have patchy abnormal signal shadows on the right frontal lobe of the brain and developed dizziness and other uncomfortable symptoms.

【Treatment Information】

In the absence of other treatments, the patient received ACTL immune cell therapy. On June 2, 2015, the peripheral blood of the patient was collected to prepare ACTL immune cells. The patient received the first reinfusion on June 17, and received a total of three reinfusions according to the ACTL treatment plan.

Monitoring the patient's serum tumor marker levels showed that the tumor markers CEA, CA125 and CA153 decreased significantly. Imaging showed that the metastatic lesions in the brain of the patient were significantly reduced.

【in conclusion】

ACTL immune cells are used alone to treat lung cancer brain metastases, and the effect is obvious. The patient's tumor marker levels began to decline during the treatment; after receiving four treatments, imaging revealed that the metastatic lesions in the patient's brain were significantly reduced. The patient's quality of life improved significantly.

The following are the results of tumor marker detection and imaging examination chart.